Literature DB >> 12837457

ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction.

Andreas Eisenhardt1, Herbert Sperling, Ekkehard Hauck, Hartmut Porst, Christian Stief, Herbert Rübben, Norbert Müller, Winfried Siffert.   

Abstract

OBJECTIVES: To examine a potential association between the response to the phosphodiesterase-5 inhibitor sildenafil and angiotensin-converting enzyme (ACE), as well as NOS3 G894T genotypes in patients with erectile dysfunction (ED). An insertion/deletion (I/D) polymorphism in the gene encoding the ACE and a single nucleotide exchange polymorphism (G894T) in the gene NOS3 encoding endothelial nitric oxide synthase have been associated with cardiovascular disorders.
METHODS: The response to sildenafil in 113 men with ED was monitored according to the patients' diaries. ACE and NOS3 genotypes were determined in patients with ED and in 108 healthy male blood donors.
RESULTS: Genotype distributions of ACE and NOS3 polymorphisms in the patient group were similar to those of the healthy control group. Analysis of the response to sildenafil revealed that 15 of 20 individuals homozygous for the ACE II genotype showed a positive erectile response after sildenafil use and only 46 of 93 D allele (combined DD and DI genotypes) carriers had a positive response (positive erectile response, odds ratio 3.07, 95% confidence interval 1.03 to 9.13, P = 0.04; chi-square test). Analysis of NOS3 genotypes revealed that 30 of 52 individuals homozygous for the G894 allele had a sufficient response to sildenafil and only 4 of 12 patients homozygous for the 894T allele had a sufficient erection.
CONCLUSIONS: It appears that patients with elevated ACE serum concentrations, as associated with the D allele of the ACE I/D polymorphism, are less likely to respond to sildenafil.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12837457     DOI: 10.1016/s0090-4295(03)00137-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

Review 1.  [Single base polymorphisms and erectile dysfunction].

Authors:  A Eisenhardt; H Rübben; H Sperling
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

2.  Pilot genome-wide association search identifies potential loci for risk of erectile dysfunction in type 1 diabetes using the DCCT/EDIC study cohort.

Authors:  James M Hotaling; Daryl R Waggott; Jack Goldberg; Gail Jarvik; Andrew D Paterson; Patricia A Cleary; John Lachin; Aruna Sarma; Hunter Wessells
Journal:  J Urol       Date:  2012-06-15       Impact factor: 7.450

Review 3.  [Genetic aspects of erectile dysfunction].

Authors:  A Eisenhardt; H Sperling; H Rübben
Journal:  Urologe A       Date:  2015-05       Impact factor: 0.639

4.  Association of coronary artery disease, erectile dysfunction, and endothelial nitric oxide synthase polymorphisms.

Authors:  Jaroslav Meluzín; Anna Vasků; Vladimír Kincl; Roman Panovský; Tat'ána Srámková
Journal:  Heart Vessels       Date:  2009-05-24       Impact factor: 2.037

Review 5.  Sexual dysfunction in essential hypertension: myth or reality?

Authors:  Michael Doumas; Stella Douma
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-04       Impact factor: 3.738

Review 6.  Association of endothelial nitric oxide synthase polymorphisms with an increased risk of erectile dysfunction.

Authors:  Lei Gao; Zhifeng Zhao; Fengfu Guo; Yan Liu; Jianhua Guo; Yang Zhao; Zhong Wang
Journal:  Asian J Androl       Date:  2017 May-Jun       Impact factor: 3.285

7.  CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.

Authors:  S de Denus; J L Rouleau; D L Mann; G S Huggins; N L Pereira; S H Shah; T P Cappola; R Fouodjio; I Mongrain; M-P Dubé
Journal:  Pharmacogenomics J       Date:  2017-04-25       Impact factor: 3.550

Review 8.  Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection.

Authors:  Soudeh Ghafouri-Fard; Rezvan Noroozi; Mir Davood Omrani; Wojciech Branicki; Ewelina Pośpiech; Arezou Sayad; Krzysztof Pyrc; Paweł P Łabaj; Reza Vafaee; Mohammad Taheri; Marek Sanak
Journal:  Vascul Pharmacol       Date:  2020-05-11       Impact factor: 5.773

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.